The safety and efficacy of myomectomy in the treatment of recurrent uterine fibroids after HIFU
International Journal of Gynecology & Obstetrics · 2024
DOI: 10.1002/ijgo.15757 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Yi-Ming Bao und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Leiomyoma, Uterine Myomectomy, High-Intensity Focused Ultrasound Ablation, Uterine Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing, Natural Science Foundation of Chongqing Municipality.
Abstract (Originalsprache)
Objective
To evaluate the safety and efficacy of myomectomy for recurrent uterine fibroids (UFs) after high‐intensity focused ultrasound (HIFU) ablation.
Methods
This was a retrospective study. Patients who underwent abdominal myomectomy (AM) and laparoscopic myomectomy (LM) from January 2018 to December 2021 at the Three Gorges Hospital of Chongqing University were included. Among them, 73 had undergone prior HIFU ablation (Group 1), while 120 had not undergone HIFU (Group 2). Outcome measures included operating time, estimated blood loss (EBL), blood transfusion, postoperative activity times (PAT), duration of hospital stay (DOHS), and complications.
Results
The operating time was 90.0 min (70.5, 115.0) for Group 1 and 110.0 min (81.5, 130.0) for Group 2 ( P < 0.05). During all AM pathways, there were no significant differences observed between the two groups in EBL, blood transfusion, PAT, DOHS, and complications; however, operating time was shorter in Group 1. The operating time, EBL, blood transfusion, PAT, DOHS, and complications were similar in both groups during LM pathway. During the follow‐up 40 (range: 24–53) months, the rate of relief, recurrence, and reintervention in Groups 1 and 2 was 78.1% versus 74.1%, 14.6% versus 16.4%, and 3.7% versus 2.6%, respectively ( P > 0.05).
Conclusion
Myomectomy is a safe and effective surgical method for treating recurrent UFs after HIFU. Myomectomy for treating recurrent UFs resulted in a shorter operative and hospital stay, reduced blood loss, faster postoperative recovery, and fewer complications, better symptom relief rates, and lower risk of recurrence or reintervention. These findings indicate that previous HIFU ablation does not worsen the outcomes of the subsequent myomectomy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China.
- Three Gorges Hospital of Chongqing University, Chongqing, China.
- College of Medical Informatics, Chongqing Medical University, Chongqing, China.
Förderung
- Natural Science Foundation of Chongqing
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Bao, Y. M., Ma, W. W., Li, S., Jiang, L., Yang, M. J., & Chen, J. Y. (2024). The safety and efficacy of myomectomy in the treatment of recurrent uterine fibroids after HIFU. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15757
Vancouver
Bao YM, Ma WW, Li S, Jiang L, Yang MJ, Chen JY. The safety and efficacy of myomectomy in the treatment of recurrent uterine fibroids after HIFU. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15757
BibTeX
@article{Bao2024,
author = {Bao, Yi-Ming and Ma, Wang-Wa and Li, Shuang and Jiang, Li and Yang, Mei-Jie and Chen, Jin-Yun},
title = {The safety and efficacy of myomectomy in the treatment of recurrent uterine fibroids after HIFU},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
doi = {10.1002/ijgo.15757}
}
EUVIMED